TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

3A-3D , Table 4 , and Table S3 ), with the exception that the administration of post-operative CHT did not reach statistical significance in multivariate analysis in the IDH mut/ TERT mut subgroup ( p = 0.369, Table 4 ).

also in 111,027 other papers